Tim Greten, M.D., medical oncologist and gastroenterologist at the Center for Cancer Research in the National Cancer Institute, discusses a phase II clinical trial …
My name is Tim Greten.
I am a medical oncologist and gastroenterologist
at the Center for Cancer Research at the NCI
in Bethesda.
I am conducting basic research studies and
also doing clinical trials so I am a typical
physician scientist.
In our new clinical trial we are going to
treat patients with primary liver cancer,
so in other words patients that have a tumor
that arises in the liver such hepatocellular
carcinoma or cholangiocarcinoma as well as
patients who have developed metastasis in
the liver with a novel treatment.
In this particular study, we will actually
apply very different drugs from what we usually
use to treat patients with liver cancer.
We will use vancomycin to change the gut microbiome;
we know from our preclinical studies that
this changes the immune cells in the liver
and can potentially the tumor burden in the
liver.
We will combine this treatment with a second
drug – tadalofil – which we have shown
again in preclinical studies to eliminate
immune suppressor cells, which basically counter
act the immune system and thereby potentially
promote tumor growth.
The third drug that we will include in this
particular study is nivolumab – a drug currently
used to boost t-cell responses.
If a patient is interested in joining this
clinical trial, they can contact us
at 1-888-624-1937, or [email protected] or
at ccr.cancer.gov/clinical-trials

Leave A Comment

Your email address will not be published
*